I would like to refer to the article by Nunez and colleagues ¹ concerning their meta‐analysis of randomized trials of the efficacy and safety of modafinil/armodafinil in bipolar depression to raise the question of a possible shift in the treatment of this condition. The depressive phases and residual depressive symptoms are the main drivers of detrimental consequences such as poor functioning, suicidal behaviors, relapses, and development of comorbid conditions in bipolar disorders (BD).

中文翻译：

---

即将转向双相抑郁症的治疗？

我想参考Nunez及其同事的文章¹，他们对莫达非尼/阿莫达非尼在双相抑郁症中的有效性和安全性的随机试验进行了荟萃分析，提出了可能改变这种情况的问题。抑郁阶段和残余抑郁症状是有害后果的主要驱动因素，例如双相情感障碍（BD）的功能差，自杀行为，复发和合并症的发展。